Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma

Launched by SCG CELL THERAPY PTE. LTD. · Jul 10, 2024

Keywords

ClinConnect Summary

This clinical trial is testing a new treatment called SCG142 TCR T cells for patients with certain types of advanced cancers related to human papillomavirus (HPV), specifically those that are positive for HPV16 or HPV52. These cancers can include cervical, head and neck, anal, penile, vulvar, and vaginal squamous cell carcinoma. The trial is designed for patients whose cancer has not responded to at least one previous standard treatment, which could include chemotherapy or a combination of chemotherapy and immunotherapy.

To participate in this trial, patients need to have a confirmed diagnosis of squamous cell carcinoma that is advanced or has spread, and their tumor must test positive for HPV16 or HPV52. Participants should also have a measurable disease and a good performance status, meaning they are generally healthy enough to participate. The trial will not be recruiting participants just yet, but it aims to offer a new treatment option for those who have limited choices left. Throughout the trial, participants will receive the SCG142 treatment and will be monitored for its effectiveness and any side effects.

Gender

ALL

Eligibility criteria

• Main Inclusion Criteria:
• • 1. Histologically confirmed squamous cell carcinoma (SCC); may include any of the following tumor types: cervical, head and neck, anal, penile, vulvar, or vaginal.
• • 2. Tumor tissue positive for HPV16 or HPV52.
• • 3. Advanced or metastatic carcinoma with progression after at least 1 line of standard of care systemic therapies, including but not limited to combination chemotherapy and/or combination chemo-immunotherapy.
• • 4. Human leukocyte antigen (HLA)-A\*02:01 genotype.
• • 5. Measurable disease as defined by RECIST v1.1.
• • 6. Eastern Cooperative Group (ECOG) Performance Status of 0 or 1.
• • 7. Anticipated life expectancy ≥3 months.
• • 8. Adequate laboratory parameters including hematologic, renal, hepatic and coagulation function.
• Main Exclusion Criteria:
• • 1. Presence of clinically relevant or active seizure disorder, stroke, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with central nervous system (CNS) involvement.
• • 2. Active brain metastasis or leptomeningeal metastases.
• • 3. History of other malignancy within 2 years prior to Screening.
• • 4. History of organ transplant.
• • 5. Positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
• • 6. History of active cardiac disease.
• • 7. History of active pulmonary disease.
• • 8. Active, known, or suspected autoimmune disease.
• • 9. Lack of peripheral venous or central venous access, or any condition that may prevent trial sample collection and administration of SCG142.
• • 10. Prior exposure to any cell therapy including, but not limited to natural killer (NK) cells, cytokine-induced killer (CIK) cells, dendritic cells (DCs), cytotoxic T lymphocytes (CTLs), stem cell therapy, and CAR/TCR-T cell therapy.
• • 11. Allergy to LD chemotherapy (cyclophosphamide or fludarabine) and/or any component of SCG142.
• • 12. Any serious medical condition or abnormality in clinical laboratory tests.